The investigation began with a computational analysis of publicly available transcriptomic and clinical data from widely used prostate cancer cohorts. The researchers sought to identify genes whose expression patterns could reliably predict patient outcomes, a longstanding goal in the field of precision oncology. Using differential expression analysis to pinpoint genes that behaved differently between tumor and healthy tissue, the team then applied LASSO-Cox regression, a statistical technique that penalizes overly complex models to prevent overfitting and select only the most robust predictors. The result was a compact three-gene prognostic signature consisting of MECR, HVCN1, and NGFR. What makes this finding particularly striking is the model’s performance: the three-gene combination independently predicted patient survival and outperformed conventional clinicopathological variables such as stage, grade, and prostate-specific antigen levels, which clinicians have relied upon for decades. In clinical practice, this kind of molecular signature could eventually help stratify patients at diagnosis, identifying those who need intensified surveillance or more aggressive intervention even when traditional indicators appear reassuring.

Of the three genes in the signature, MECR emerged as the standout. Short for mitochondrial enoyl-CoA reductase, MECR encodes an enzyme embedded in the fatty acid synthesis machinery of mitochondria, and it was the only member of the trio whose elevated expression was associated with poor prognosis. This connection to lipid metabolism is scientifically significant because cancer cells are notorious for rewiring their metabolic programs to support rapid proliferation. Fatty acid synthesis, in particular, provides building blocks for membranes, energy storage, and signaling molecules that tumors need as they grow and spread. The observation that a mitochondrial enzyme in this pathway correlates with worse outcomes in prostate cancer suggested to the researchers that MECR might not merely be a biomarker but an active participant in the disease process.

To test this hypothesis, the team turned to functional experiments in prostate cancer cell lines. When they reduced MECR expression, the cancer cells lost several of their malignant advantages. Proliferation slowed, migration—the cellular behavior that underpins metastasis—was impaired, and the cells showed increased apoptosis-related nuclear morphological changes, meaning they displayed the characteristic structural hallmarks of programmed cell death. These results indicate that MECR helps prostate cancer cells resist apoptosis, the built-in suicide program that healthy organisms use to eliminate damaged or dangerous cells. Tumors that evade apoptosis are notoriously difficult to treat with chemotherapy and radiation, both of which work in part by triggering this death pathway. A gene that suppresses apoptosis therefore represents an attractive therapeutic target, because inhibiting it could potentially re-sensitize tumors to existing treatments.

The mechanistic story deepened when the researchers probed how MECR exerts its effects. Their experiments revealed that MECR regulates the activity of the PI3K/AKT pathway, one of the most frequently activated signaling cascades in human cancer. This pathway functions as a master switch for cell survival, growth, and metabolism; when constitutively active, it drives uncontrolled proliferation and protects cells from dying. By modulating PI3K/AKT signaling, MECR appears to sit upstream of processes that are central to tumor maintenance. Beyond this canonical cancer pathway, the team also found evidence that MECR influences immune-related cellular mechanisms, hinting that the gene’s impact extended beyond the tumor cell itself and into the surrounding microenvironment—the complex ecosystem of immune cells, fibroblasts, blood vessels, and signaling molecules that envelops every tumor.

That hint was put to a rigorous test using immunocompetent syngeneic tumor models, laboratory systems in which tumors are grown in mice with fully functioning immune systems. This experimental design is critical because many cancer studies rely on immunodeficient mice, which cannot reveal how a tumor interacts with the immune system. When the researchers knocked down MECR in these models, tumor progression was significantly inhibited. Crucially, the suppressed tumors showed increased activation of CD8-positive T cells, the cytotoxic “killer” cells of the adaptive immune system that are responsible for recognizing and destroying cancer cells. This finding positioned MECR not just as a metabolic driver but as a potential architect of immune evasion, reshaping the tumor microenvironment in ways that keep the most potent anti-cancer immune warriors in check.

To confirm that CD8-positive T cells were genuinely responsible for the antitumor effect, the researchers performed an elegant depletion experiment. When they eliminated CD8-positive T cells from the mice, the antitumor benefits of MECR silencing were partially rescued—in other words, tumors grew more effectively again when the killer T cells were absent. This experiment demonstrated that CD8-mediated immunity is a key contributor to the therapeutic effect of suppressing MECR, cementing the link between this metabolic enzyme and the immune response against prostate cancer. The implication is profound: targeting MECR could simultaneously deprive tumors of a metabolic advantage and unleash the immune system against them, a dual mechanism that mirrors the goals of modern combination immunotherapy.

The broader context of this work touches one of the most pressing challenges in prostate cancer treatment. While immune checkpoint inhibitors have revolutionized the treatment of many cancers, prostate cancer has proven remarkably resistant to these therapies, in part because prostate tumors typically foster an immunologically “cold” microenvironment with few active T cells. Understanding how individual metabolic genes remodel this microenvironment could reveal why prostate cancers exclude or suppress immune cells and point to strategies for reversing that process. The authors of the new study frame their findings as a contribution to understanding immune evasion and the therapeutic resistance that flows from it. By integrating tumor-intrinsic mechanisms—proliferation, migration, apoptosis resistance—with immune-associated remodeling, the study offers a more holistic view of how prostate cancer progresses than approaches that examine tumor cells in isolation.

There are also translational implications for prognostic modeling. A three-gene signature that outperforms standard clinical variables would be relatively straightforward to implement in pathology laboratories using routine molecular techniques such as quantitative PCR or RNA sequencing. If validated in prospective clinical cohorts, the MECR-HVCN1-NGFR signature could help clinicians identify patients whose apparent low-risk disease nonetheless carries molecular features of aggressiveness, guiding decisions about active surveillance versus active treatment. Meanwhile, MECR itself, as the sole poor-prognosis gene in the panel and a mechanistically validated driver, stands out as a candidate for drug development. Small molecules targeting mitochondrial fatty acid synthesis enzymes are an emerging area of cancer pharmacology, and this study provides preclinical evidence that such an approach could pay dividends in prostate cancer specifically.

The study was approved by the Ethics Committee of Nanjing Medical University, conducted in accordance with the Declaration of Helsinki with written informed consent from all human participants, and animal experiments complied with institutional ethical regulations and ARRIVE guidelines. The research team, spanning the Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, the Affiliated Suzhou Hospital of Nanjing Medical University, and the Second Affiliated Hospital of Soochow University, published the work as an open-access article, making the data freely available to researchers worldwide. As with all preclinical research, the path from laboratory finding to clinical application will require further validation, including studies in larger patient cohorts and the development of pharmacological tools to inhibit MECR in humans. But the convergence of prognostic value, mechanistic clarity, and immune relevance in a single gene is rare in cancer research, and it is precisely this convergence that makes MECR a target worth watching. If future studies confirm these findings, suppressing MECR could become a strategy that attacks prostate cancer on two fronts at once—starving the tumor of its metabolic advantages while stripping away the defenses it uses to hide from the immune system.

Cells cannot grow indefinitely by simply consuming nutrients. Growth requires a coordinated supply of energy, carbon building blocks and molecular machinery, but it also creates damaged proteins, defective organelles and other waste that must be removed. Autophagy provides one of the cell’s principal quality-control systems. During autophagy, a small membrane structure called a phagophore expands around selected cellular material. The phagophore then closes to form an autophagosome, a double-membraned compartment that delivers its contents to lysosomes for degradation and recycling. This process can supply nutrients during starvation, remove potentially harmful debris and help cells recover from stress. Yet autophagy must be carefully controlled. Too little can allow damage to accumulate, while excessive or mistimed activity can consume essential components. The new findings place PGAM1 at an early decision point in this process, where metabolic status and autophagy initiation can be coordinated rather than regulated as separate cellular programs.

PGAM1 has traditionally been understood as a glycolytic enzyme. In glycolysis, a chain of reactions converts glucose into pyruvate while generating usable energy and producing intermediates that can be diverted into the synthesis of nucleotides, lipids and amino acids. PGAM1 catalyzes the reversible conversion of one phosphorylated sugar intermediate into another, helping maintain the flow of carbon through the pathway. Cancer cells frequently increase glycolytic activity even when oxygen is available, a metabolic pattern associated with rapid biomass production and adaptability. The study shows that PGAM1’s importance extends beyond this catalytic function. When researchers examined complementary yeast and mammalian systems, they found that the protein also acts as a physical organizer for the machinery that initiates autophagy. This distinction is crucial: the same protein can promote growth through its enzyme activity while supporting stress survival through a separate structural role.

The autophagy function of PGAM1 appears to depend on its ability to recruit phosphatidylinositol 3-kinase complex I to the phagophore assembly site. This complex is a central component of the molecular machinery that marks and organizes the membrane where an autophagosome will form. By helping bring the complex to the correct location, PGAM1 effectively licenses the earliest stages of autophagosome biogenesis. Without this recruitment step, the cell may possess the individual ingredients needed for autophagy but fail to assemble them into a functional initiation site. The finding suggests that PGAM1 is not merely associated with autophagy as a downstream consequence of altered metabolism. It operates directly at the point where the autophagic membrane-building program is switched on. In molecular terms, PGAM1 functions as a scaffold: a platform that assembles proteins into a productive complex without necessarily changing those proteins through an enzymatic reaction.

The researchers further found that this role is regulated by phosphorylation mediated by Atg1 in yeast and ULK1 in mammals. These related protein kinases are among the best-known initiators of autophagy, responding to conditions such as nutrient depletion. Phosphorylation changes the behavior of a target protein by adding a phosphate group to specific amino acids, potentially altering its shape, location or binding partners. Under starvation conditions, Atg1 or ULK1-mediated phosphorylation enhances PGAM1’s interaction with Atg14, a component associated with the autophagy-initiation machinery. This provides a direct biochemical route through which stress signals can redirect a glycolytic enzyme toward autophagy control. Rather than treating metabolism and autophagy as independent responses, the mechanism allows a cell to use information about nutrient availability to modify the physical assembly of its recycling apparatus. It also indicates that PGAM1’s checkpoint function is dynamically regulated, becoming especially important when external nutrients are scarce.

Genetic experiments described in the study indicate that PGAM1’s autophagy-regulatory activity is essential and evolutionarily conserved. Conservation across yeast and mammalian systems suggests that the mechanism arose early and has been retained because it solves a fundamental cellular problem: how to maintain growth when nutrients are plentiful and preserve viability when those nutrients disappear. The researchers also found that the autophagy function can be separated genetically from PGAM1’s role in glycolysis. In other words, disrupting the protein’s ability to support autophagy does not simply amount to shutting down its metabolic enzyme activity, and vice versa. This separation strengthens the case that PGAM1 has two distinct molecular identities within the cell. One supports the movement of glucose-derived metabolites through glycolysis; the other helps organize the machinery required to initiate autophagosome formation. Together, the two activities allow cells to match biomass production with quality control and stress tolerance.

That coordination becomes particularly significant in cancer. Tumour cells are under continuous pressure: they must divide rapidly, secure enough nutrients to make new cellular material and survive conditions created by poor blood supply, crowding and fluctuating oxygen or nutrient levels. Increased PGAM1 expression, according to the findings, enhances both glycolytic flux and autophagy capacity. The first effect can provide energy and biosynthetic intermediates for proliferation. The second can help cancer cells recycle internal resources and remove damage when their environment becomes difficult. This combination could give tumour cells a form of metabolic flexibility, allowing them to grow under favorable conditions and endure unfavorable ones. The study reports that disrupting either PGAM1 function markedly impairs tumour growth. That result suggests that cancer cells may depend on the enzyme’s two activities simultaneously, rather than relying only on its established contribution to glycolysis.

The findings could influence how researchers think about targeting metabolic proteins in cancer. A drug designed only to block PGAM1’s catalytic activity might reduce glycolytic output while leaving the protein’s autophagy-scaffolding function intact. Conversely, an intervention that prevents PGAM1 from recruiting autophagy-initiation factors could weaken tumour stress tolerance without necessarily eliminating all glycolytic activity. The study therefore points to a potential therapeutic vulnerability at the interface between metabolism and autophagy. However, the discovery does not by itself establish a treatment or show how such an approach would behave in patients. Autophagy is also essential for normal cells, particularly those exposed to nutrient limitation or other physiological stresses, so broadly suppressing the pathway could carry substantial risks. The significance of the work is instead that it identifies a more precise molecular connection—PGAM1’s interaction with the autophagy machinery—that future research can examine in detail.

More broadly, the study presents cellular survival as a balancing act governed by shared molecular components rather than by isolated pathways. Glycolysis is often described as an energy-producing route, while autophagy is commonly framed as a recycling and quality-control system. PGAM1 shows how those categories can overlap: a protein best known for processing a glycolytic intermediate can also determine whether a membrane structure for autophagy is assembled. Its phosphorylation by Atg1 or ULK1 during starvation places the enzyme within a responsive network that can shift the cell from growth toward maintenance without abandoning metabolism altogether. In cancer, that same integration appears to be exploited, coupling the production of cellular building blocks with the ability to survive stress. By revealing PGAM1 as a metabolic–autophagy checkpoint, the work provides a mechanistic explanation for how cells coordinate proliferation, recycling and resilience—and identifies a molecular junction where the biological logic of healthy adaptation can be repurposed to sustain tumour growth.

At the heart of this discovery lies the androgen receptor (AR), a well-established protein driver fueling the progression of prostate cancer. PDIA1 and PDIA5 serve as indispensable molecular chaperones, ensuring the stability and functional integrity of the AR within cancerous cells. Through complex biochemical interactions, these enzymes safeguard the AR from degradation, thereby enabling continuous oncogenic signaling that supports tumor growth. When the activities of PDIA1 and PDIA5 are inhibited, this protective effect disintegrates, triggering the destabilization and proteasomal breakdown of AR, ultimately inducing apoptosis in cancer cells and causing measurable tumor regression.

Critically, the researchers demonstrated that pharmacological inhibition of PDIA1 and PDIA5 not only undermines AR stability but also amplifies the therapeutic efficacy of enzalutamide—an androgen receptor signaling inhibitor widely used in prostate cancer treatment. This combination treatment synergistically impaired cancer cell viability far more effectively than enzalutamide alone, as confirmed in both laboratory cultured cells and multiple animal models. These results delineate a promising avenue to counteract the notorious resistance that often develops against conventional hormone therapies in advanced prostate cancer cases.

Professor Luke Selth, an eminent figure in prostate cancer research and senior author on the study, highlights the significance of the discovery: “We have uncovered a previously uncharacterized mechanism that prostate cancer cells exploit to shield the androgen receptor, a pivotal oncogenic driver. Targeting PDIA1 and PDIA5 disrupts this defense, rendering tumors more susceptible to existing anti-androgen therapies such as enzalutamide.” This insight opens a new frontier in the quest for therapeutic regimens that can overcome the adaptive resistance often encountered during treatment.

Contributing to the robustness of this research, lead author Professor Jianling Xie noted that the dual blockade of PDIA1 and PDIA5 exhibited potent anti-cancer effects in patient-derived tumor samples and in vivo mouse models, both of which closely mimic human tumor biology. “Our data strongly support the translational potential of this combination therapy, warranting further rigorous clinical trials that could eventually improve patient outcomes,” Dr. Xie explained, now continuing her research at South China University of Technology.

Beyond their role as molecular bodyguards of the androgen receptor, PDIA1 and PDIA5 were found to exert additional oncogenic functions by regulating cellular stress responses and bioenergetic homeostasis. The study highlighted that inhibiting these enzymes results in mitochondrial dysfunction, impairing energy production within cancer cells and elevating reactive oxygen species (ROS). This oxidative stress exacerbates cellular damage, synergizing with AR destabilization to compound tumor cell lethality.

This multifaceted attack—simultaneously impairing AR signaling and cellular metabolism—positions PDIA1 and PDIA5 as uniquely attractive therapeutic targets. According to Dr. Xie, “By cutting off both the fuel supply and the engine driving prostate cancer, we effectively starve and immobilize the tumor’s capacity to survive and expand.” This dual mechanism is particularly notable in the context of developing treatments that can circumvent therapeutic resistance and target cancer on multiple biological fronts.

However, Professor Selth cautioned that current inhibitors targeting PDIA enzymes are still in the developmental phase. While promising, some existing compounds lack specificity and may damage healthy cells, thereby posing safety concerns. Future research efforts will focus on the rational design of more selective and less toxic PDIA inhibitors, optimizing their pharmacological profiles to enhance clinical applicability and minimize off-target effects.

The relevance of these findings is underscored by the epidemiological burden of prostate cancer, which ranks as the second most common cancer among men globally. Despite advances in hormone therapy and AR-directed drugs, resistance remains a formidable barrier to long-term disease control, especially in advanced and metastatic stages. The identification of PDIA1 and PDIA5 as central players in this resistance mechanism heralds a potential paradigm shift in therapeutic strategies aimed at durable cancer suppression.

The study was funded by a consortium of organizations committed to cancer research, including Cancer Council SA, Cancer Council NSW, the Flinders Foundation, the Movember Foundation, the Prostate Cancer Foundation of Australia, The Hospital Research Foundation, Cancer Australia, the Masonic Charities Trust, the Australian Research Council, and several international collaborators. This collaboration underscores the global priority placed on tackling prostate cancer through innovative scientific inquiry.

Full elucidation of the mechanisms by which PDIA1 and PDIA5 stabilize the androgen receptor and support cancer metabolism provides a valuable framework for the development of next-generation combination therapies. Such approaches may not only extend survival but also improve the quality of life for men afflicted with this disease. The prospect of therapies that more comprehensively disrupt cancer cell survival pathways offers renewed hope in the ongoing battle against prostate cancer.

Moving forward, the translation of this preclinical research into clinical success will depend on meticulous drug development, coupled with carefully designed clinical trials to establish efficacy and safety in humans. The path from bench to bedside may be challenging, but the evidence presented heralds a promising future for men confronting this diagnosis.

Subject of Research: Animals
Article Title: Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival
News Publication Date: 17-Oct-2025
Web References: DOI: 10.1073/pnas.2509222122
References: Jianling Xie et al., PNAS, 2025;122:e2509222122
Image Credits: Professor Luke Selth, Flinders Health and Medical Research Institute (FHMRI) and College of Medicine and Public Health, Flinders University
Keywords: prostate cancer, androgen receptor, PDIA1, PDIA5, enzyme inhibition, enzalutamide, therapeutic resistance, mitochondrial dysfunction, oxidative stress, combination therapy, molecular chaperones, cancer metabolism